Source-grounded facts extracted from Nuvectis Pharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Nuvectis Pharma, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 5, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2026.”
Nuvectis Pharma, Inc. reported first quarter ended March 31, 2024 results: net income $4.2 million.
“First Quarter 2024 Financial Results Cash, and cash equivalents were $19.5 million as of March 31, 2024, compared to $19.1 million as of December 31, 2023. The increase of $0.4 million in the cash balance in the first quarter of 2024 is a result of the utilization of the at-the-market facility, partially offset by the operating expenses for the quarter. The Company's net loss was $4.2 million for the three months ended March 31, 2024, compared to $4.0 million for the three months ended March 31, 2023, an increase in net loss of $0.2 million.”
Nuvectis Pharma, Inc. reported the fiscal year ended December 31, 2023 results: net income $22.3 million.
“The Company's net loss was $22.3 million for the year ended December 31, 2023, compared to $19.1 million for the year ended December 31, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.